BIONTECH SE-ADR (BNTX) Stock Price, Forecast & Analysis
NASDAQ:BNTX • US09075V1026
BNTX Key Statistics, Chart & Performance
The current stock price of BNTX is 110.42 USD. In the past month the price decreased by -6.42%. In the past year, price decreased by -7.99%.
BNTX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to BNTX. When comparing the yearly performance of all stocks, BNTX turns out to be only a medium performer in the overall market: it outperformed 47.72% of all stocks.
BNTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BNTX. BNTX has only an average score on both its financial health and profitability.
BNTX Financial Highlights
Over the last trailing twelve months BNTX reported a non-GAAP Earnings per Share(EPS) of -2.81. The EPS decreased by -20.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.68% | ||
| ROE | -3.09% | ||
| Debt/Equity | 0.01 |
BNTX Forecast & Estimates
28 analysts have analysed BNTX and the average price target is 140.72 USD. This implies a price increase of 27.44% is expected in the next year compared to the current price of 110.42.
For the next year, analysts expect an EPS growth of -19.54% and a revenue growth 4.52% for BNTX
BNTX Ownership
BNTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.45 | 404.235B | ||
| AMGN | AMGEN INC | 16.66 | 204.477B | ||
| GILD | GILEAD SCIENCES INC | 16.94 | 189.501B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 119.327B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.84 | 83.747B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.66 | 43.95B | ||
| INSM | INSMED INC | N/A | 32.227B | ||
| NTRA | NATERA INC | N/A | 29.989B | ||
| BIIB | BIOGEN INC | 12.63 | 28.491B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.499B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BNTX
Company Profile
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Company Info
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ 55131 DE
CEO: Ugur Sahin
Employees: 6772
Phone: 4949613190840
BIONTECH SE-ADR / BNTX FAQ
Can you describe the business of BIONTECH SE-ADR?
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
What is the stock price of BIONTECH SE-ADR today?
The current stock price of BNTX is 110.42 USD. The price increased by 2.29% in the last trading session.
Does BIONTECH SE-ADR pay dividends?
BNTX does not pay a dividend.
How is the ChartMill rating for BIONTECH SE-ADR?
BNTX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of BIONTECH SE-ADR (BNTX)?
BIONTECH SE-ADR (BNTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.81).
What is the expected growth for BNTX stock?
The Revenue of BIONTECH SE-ADR (BNTX) is expected to grow by 4.52% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for BIONTECH SE-ADR?
BIONTECH SE-ADR (BNTX) has a market capitalization of 26.55B USD. This makes BNTX a Large Cap stock.